Opto Circuits (India) Ltd - Stock Valuation and Financial Performance

BSE: 532391 | NSE: OPTOCIRCUI | Medical Equipment/Supplies/Accessories | Small Cap

Opto Circuits (I) Share Price

1.78 0.00 0.00%
as on 23-May'22 18:01

DeciZen - make an informed investing decision on Opto Circuits (I)

M-Cap below 100cr DeciZen not available

Opto Circuits (India) stock performance -

P/E Ratio (SA):
0.00
Market Cap:
53.5 Cr.
52-wk low:
1.8
52-wk high:
1.9

Is an attractive stock to invest in?

1. Is a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Opto Circuits (India) Ltd is a below average quality company.

2. Is undervalued or overvalued?

The key valuation ratios of Opto Circuits (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Opto Circuits (I):

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Opto Circuits (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
ROCE % 19.2%15%12.9%4.5%-6.3%0.7%-19.9%0.7%2.1%-106.6%-
Value Creation
Index
0.40.1-0.1-0.7-1.5-1.0-2.4-1.0-0.9-8.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 60367069926314676.750.463.510562.60
Sales YoY Gr.-11%4.4%-62.4%-44.4%-47.5%-34.3%26%65.2%-40.3%-
Adj EPS 9.89.7101.8-2.9-0.7-150.31.1-11.6-5.3
YoY Gr.--1.4%3.7%-82.1%-263.7%NANANA220.6%-1163.3%-
BVPS (₹) 43.950.16061.85352.336.839.139.11.3-4
Adj Net
Profit
23823424343.3-70.9-18-3649.832.7-349-159
Cash Flow from Ops. 118-29.5-92.9-15.755.733557.446.64221.3-
Debt/CF from Ops. 6.1-22.3-8.8-5615.92.112.411.812.623-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -22.3%-15.6%7.5%-40.3%
Adj EPS -201.9%NANA-1163.3%
BVPS-32.4%-52.4%-67.2%-96.7%
Share Price -21.3% -10.8% -5.8% -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on
Equity %
24.720.618.22.9-5.1-1.4-33.712.8-57.4389.7
Op. Profit
Mgn %
4041.739.443.736.530.629.831.839.826.9-4905.1
Net Profit
Mgn %
39.43534.716.5-48.5-23.5-722.815.531.2-556.7-63493.1
Debt to
Equity
0.70.50.60.60.70.60.80.50.512.5-
Working Cap
Days
3756099062,7744,9588,64610,2396,4713,9494,62462,800
Cash Conv.
Cycle
2342643601,3082,3302,2637344013-122-5,29,655

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Opto Circuits (India) Ltd.

Standalone Consolidated
TTM EPS (₹) -5.3 -4.3
TTM Sales (₹ Cr.) 0.3 106
BVPS (₹.) -4 -7.7
Reserves (₹ Cr.) -421 -531
P/BV -0.44 -0.23
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 1.78 / 1.94
All Time Low / High (₹) 1.45 / 262.90
Market Cap (₹ Cr.) 53.5
Equity (₹ Cr.) 300.6
Face Value (₹) 10
Industry PE 75.2

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 40.2 5.539.1 3.841 9.443.4 13.1
Adj EPS (₹) 1.8 -50.11.6 -41.10.9 -57.41.7 -9.3
Op. Profit Mgn % 11.22 -683 bps12.08 -399 bps12.05 -192 bps10.56 -233 bps
Net Profit Mgn % 4.20 -464 bps3.73 -280 bps2.25 -300 bps3.92 -50 bps

Management X-Ray of Opto Circuits (I):

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:18.52%Institutions:0.98%Non-Institutions:80.5%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep18Dec18Mar19Jun19Sep19Dec19Mar20Jun20Sep20Dec200%5%10%15%20%25%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Opto Circuits (I)

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

Opto Circuits: Valuation Suspended - 07 Jan 2013

In our last update about Opto Circuits, we had informed you that the ‘Stop Loss’ trigger for the company had been hit and investors were advised to consider exiting from the stock. We have been monitoring Opto Circuits stock closely since its price-fall started. You can read our previous reports here. Since our last update, the stock price has risen slightly and is currently quoting at Rs. 111 (as on 7th January).

We met with the investor relations team of the company in order to get more insights and understanding about the company’s strategy and plans to go ahead. However, the information provided did not help us get good clarity about how the company plans to improve its financial performance going ahead. In addition to this, some new information provided to us by one of our subscribers, Mr. Mahesh Asrani has further made us more sceptical about the company and its financials.

The major concerns which are expected to weigh on the stock are:

1) Business model of the company under question:

Opto Circuits has followed an inorganic strategy of growth, acquiring around 10 companies over the last decade. While this has resulted in huge growth in Sales and profits, Opto’s cash generation has been consistently poor. This can largely be attributed to poor working capital management. The company has always stated that this is due to the nature of its business but over a period of time, this has hurt the company dearly.

With poor cash generation, Opto’s management has had to fund acquisitions by raising debt. Company has also diluted equity either by private placement or by issuing bonus shares. As a result promoter shareholding has come down and is currently 28.17% as of September 2012. What is concerning, is that while the company has had problems generating cash flows for sustaining and growing operations, it has continued to pay out high dividends. While the dividend payout ratio has come down over the years, in absolute terms the dividend paid out by the company is large. For e.g. in FY 2012, while it generated just Rs. 126 Cr. of cash flow from operations on a consolidated basis, it paid out Rs. 84 Cr. of dividends to its investors. This number seems very high if we also consider that Opto ended up investing cash to the tune of Rs. 337 Cr. in its business. Management could do well to stop dividend payouts altogether and invest the corresponding monies into the business rather than borrowing or diluting equity further.

The management has stated that now the company is not looking for any more acquisitions and will look to integrate the ones already made so as to improve performance. Latest quarterly results have been below our expectations with sales growth slowing down in some segments. Company is focusing on reducing its working capital needs but this may take some time.

The board of Directors has approved issue of convertible warrants to promoters which will infuse cash to the tune of Rs. 29 Cr. in the company. However, this won’t solve much of the problems faced by the company. We feel Opto’s business model has some structural issues which need to be looked at and based on the available evidence and information it remains to be seen whether they are corrected.

2) Doubtful accounting practices:

Adding to our concerns is the possibility of Opto following some doubtful accounting practices. A report shared by one of our subscribers Mr. Mahesh Asrani  delves into possible discrepancies in the way financials for its subsidiaries, tax payments, salaries, restructuring exercises and contingent liabilities are reported.

3) Negative sentiments related to credit rating suspension:

In one of our earlier updates, we had written about ICRA downgrading its rating of Opto’s long-term loan facilities and suspending its rating on Opto’s short-term loan facilities. The reason for suspension was cited as lack of requisite information provided by company. However, Opto management claimed that they had terminated the services of ICRA (in July) much before the report had come out and given the mandate of rating to CRISIL. CRISIL was expected to come out with its rating report in few days after this incident; however the report is yet to come out. In the quarterly conference call, management stated that CRISIL wanted financials for 2 quarters of FY 2013 which were now provided. The report is not out yet and it remains to be seen when it will be out. In summary, the entire incident has continued to weigh on the stock price.

So, what should investors do?

Considering all these issues, we are suspending our colour coding and valuation guidance for Opto Circuits. In our last update, we had advised investors to exit the stock as the stop loss was activated. We re-iterate our view and advice investors to exit the stock. We also advise new investors to not make any investments in this stock due to the above stated concerns. We will be monitoring the company closely and will keep our members updated about any new information.

Opto Circuits: Stop Loss triggered - 26 Nov 2012

In our last update about Opto Circuits sent out on 24th August, 2012, we had explained the reasons for the price fall and had advised our subscribers to remain cautious about the stock and not make any fresh investments in the stock. You can read this report here.

Since then, the stock price has fallen and is down by ~20% (Rs. 102.95 as on 23rd November). The company recently announced its Q2FY13 results which were below our expectations. The biggest concern was that the company slipped up once again with respect to working capital management. The quarter saw receivables days increasing to 160 days from 131 days at the end of March 2012.

CRISIL, which was given the new credit rating mandate, was expected to come out with a report. However, this has also gotten delayed and the management stated in the concall that they expect this report to come out soon. The reason given for the delay was that CRISIL wanted financial numbers for 2 quarters which were provided by the company after announcement of the results.

Apart from these short term issues, as mentioned in the last update, the structural issues like a stretched working capital cycle and inadequate cash flows continue to remain. The company has stated its plans to improve the situation but this will take time and is not expected to happen soon.

The fall in the stock price over the last few days has triggered our Stop Loss for Opto Circuits. Considering this and the absence of a strong positive catalyst which could drive the stock prices up in the short term, we advise investors to consider exiting the stock.  

We have scheduled a meeting with the management of the company in the first week of December and intend to get a detailed understanding about the company’s plans going ahead. We will be coming out with a detailed analysis post our visit. We also expect the CRISIL report to be out by then which will provide some important inputs. Investors can then take a call on whether to consider investing in the stock again based on our updated evaluation guidance.

Opto Circuits : Reasons for price fall - 24 Aug 2012

Opto Circuits India Ltd (OCI) is engaged in the development, manufacture, distribution and marketing of medical equipment and devices. Its focus is in the niche areas of invasive (instruments that require the entry of a needle, or other instrument into a part of the body e.g. coronary stents) and non-invasive (instruments used to monitor health, but that do not enter body for e.g. Digital thermometer, sensors etc.) segments. Non-Invasive product segment contributes 75% to overall revenues of OCI and balance comes from Invasive. Opto Circuits is based in Bangalore, India and operates out of offices established in USA, Europe, South-East Asia, Latin America and the Middle East

So, what’s the problem?

The Opto Circuits stock has shed over 40 % of its value over the last six months. Especially over the last week, the stock price has fallen around 13%.

The poor performance of the stock can be attributed to concerns relating to high level of debt – which was taken for its aggressive expansion plans – and reduction in margins. Historically, the company has also had a stretched working capital situation owing to high receivable and inventory days which it has attributed to the nature of the business. All these things have affected the cash flows of the company. Further, on August 9, there was also news that ICRA had suspended the rating assigned to the Rs. 538 Cr. fund based facilities of Opto Circuits which led to a fall in the stock price.
Opto has completed 11 acquisitions between 2001 and 2010 – which has led to a debt of close to Rs. 1000 Cr. on its books. While it does not plan to buy out any more firms for now it still has projected a capital expenditure of Rs. 250 Cr. towards setting up manufacturing facilities, which again will eat into a large part of its free cash flows this year.

Opto’s products can be divided into 2 segments – Invasive and Non-invasive products. The invasive devices segment is a high-margin business. However, the company's last three acquisitions in 2010 were in the low-margin non-invasive segment. This resulted in its operating margins getting impacted last fiscal. The company now again intends to focus on the invasive segment by raising Rs 2500 crore. The invasive segment contributes only one-fifth to the company's consolidated revenues.

What does the company management have to say about this?

The CMD of the company Mr. Vinod Ramnani in an interview with CNBC TV18 has said that the company is not facing any stress on the liquidity position and its working capital cycle remains at 135-140 days. The company has shown some improvement and has reduced its working capital cycle by 20 days in the last quarter. It has provided a revenue growth guidance of 15-20% and EBITDA margins of 25-26% this fiscal.

About the suspension of the ICRA rating, management has stated that ICRA are no longer service providers for Opto and the new credit rating mandate has been given to CRISIL. This mandate was given in July , before the report by ICRA was released (August 9). The new credit rating by CRISIL will be out in some days. The company has also put up letters given by secured lenders (banks like Standard Chartered, IndusInd and DBS) which state that the company has been regular as far as debt repayment has been concerned.

So, what should you do?

While the recent price movement could be said to be due to market sentiments, the concerns about a stretched working capital situation remain. The management has also said that it will take around six quarters for the company to generate free cash flows once the bulk of the capital expenditure is incurred. Thus, in the short term the balance sheet will most likely remain under stress for a while despite the recent strong quarterly performance.

We advise our subscribers to remain cautious about the stock and not make any fresh investments in the stock for the time being. We are monitoring the stock continuously and will keep our subscribers updated about any changes in the valuation guidance.

Key Ratios of Opto Circuits (I)

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Poly Medicure 2,539.4 31 (1.2%) Small Cap 1,307 31.1 18.4 80.6 9.6
Hemant Surgical Inds 105.9 0 (0%) Small Cap 106 9.4 8.4 11.3 2
Nureca Ltd. 248 -4 (-1.6%) Small Cap 94.5 -7.2 -6.9 - 1.3
Prevest Denpro 504.3 -7.7 (-1.5%) Small Cap 56.4 14.7 28.2 34.9 6.1
Centenial Surgical 131.3 0 (0%) Small Cap 51.2 -0.6 2.2 - 1.6
Raaj Medisafe India 68.8 0 (0%) Small Cap 43.2 2.5 7.7 27.1 3.9
GKB Ophthalmics 74.2 -2.7 (-3.6%) Small Cap 31.2 -9.9 -11.2 - 1.9
Amkay Products 45 -1 (-2.2%) Small Cap 31.1 3 8.5 15.1 1.8
Shree Pacetronix 70.5 0 (0%) Small Cap 22 4.8 15.1 14.8 1.9
KMS Medisurgi 125 0 (0%) Small Cap 13.9 1.7 3.6 72 5.7
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Sales603.20669.74699.25262.78146.1476.6750.3863.46104.8262.61
Operating Expenses 361.70390.40425.79149.5598.0553.2235.3843.2863.1045.80
Manufacturing Costs6.304.249.249.149.836.523.902.802.982.51
Material Costs337.59363.56391.91119.4364.1828.0216.0425.0640.2925.09
Employee Cost 6.648.259.539.9510.079.788.217.669.419.04
Other Costs 11.1814.3515.1111.0313.968.907.237.7610.429.16
Operating Profit 241.50279.34273.46113.2348.0923.461520.1841.7216.81
Operating Profit Margin (%) 40.0%41.7%39.1%43.1%32.9%30.6%29.8%31.8%39.8%26.8%
Other Income 36.391.340.0300.0100.170.253.162.94
Interest 24.9336.652253.5857.8231.527.851.361.150.85
Depreciation 5.916.056.617.929.739.508.799.068.813.26
Exceptional Items 0000-181.400-362.5700-1,207.16
Profit Before Tax 247.05237.97244.8751.73-200.84-17.55-364.0410.0134.92-1,191.52
Tax 2.683.213.839.570.670.470000
Profit After Tax 244.38234.77241.0442.16-201.51-18.02-364.0410.0134.92-1,191.52
PAT Margin (%) 40.5%35.1%34.5%16.0%-137.0%-23.5%-722.0%15.8%33.3%-1,903.0%
Adjusted EPS (₹)10.19.710.01.7-8.3-0.7-15.00.41.2-39.6
Dividend Payout Ratio (%)34%31%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20

Equity and Liabilities

Shareholders Fund 1,062.831,213.111,454.151,496.311,284.991,266.97892.321,123.311,176.5039.02
Share Capital 186.40242.32242.32242.32242.32242.32242.32287.50300.63300.63
Reserves 876.43970.791,211.831,253.991,042.671,024.65650835.81875.87-261.60
Minority Interest0000000000
Debt716.78649.25800.79871.41872.95701.79705.95541.14522.11488.89
Long Term Debt148.1380.017.753.8851.6152.90104.77101.3030.61
Short Term Debt568.65641.24800.78863.66869.07650.18653.04436.37420.81458.27
Trade Payables6.6812.1355.4237.23117.78140.257.6220.0631.9254.46
Others Liabilities 257.29130.80164.41118.41148.15149.3496.1289.9393.3061.49
Total Liabilities 2,043.592,005.282,474.772,523.352,423.862,258.351,702.021,774.431,823.83643.85

Fixed Assets

Gross Block98.6699.30152.22152.44151.81147.55148.97149.19149.0344.88
Accumulated Depreciation19.3725.4031.3239.2456.8962.5671.3680.4288.9232.66
Net Fixed Assets79.2973.90120.90113.2094.9184.9877.6168.7760.1112.22
CWIP 1.201.281.291.290102.10102.17157.44157.940
Investments 1,114.39381.66381.66381.66381.66381.66381.66436.57447.04202.36
Inventories245.21265.45360.53438.87341.65280.99108.0427.0226.1817.23
Trade Receivables228.78257.33584.26615.016460.805.3812.0823.3223.78
Cash Equivalents 117.4645.602.162.311.762.760.780.971.210.31
Others Assets257.25980.061,023.96971.02957.881,405.041,026.371,071.581,108.03387.96
Total Assets 2,043.592,005.282,474.772,523.352,423.862,258.351,702.021,774.431,823.83643.85

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Cash Flow From Operating Activity 118.02-29.50-92.94-15.7355.68334.7357.3646.5841.9621.30
PBT 247.05237.97244.8751.73-200.84-18.02-364.0410.0134.92-1,191.52
Adjustment 6.3142.4228.5961.3267.7242.81271.6010.428.541,211.11
Changes in Working Capital -132.66-306.69-362.57-119.21189.48309.94149.8126.16-1.51.72
Tax Paid -2.68-3.21-3.83-9.57-0.6700000
Cash Flow From Investing Activity -572.02145.70-19.18-0.220.04-48.80-55.65-0.77-11.4218.96
Capex -4.82-0.75-53.67-0.220.04-103.47-1.49-0.22-0.07-0.03
Net Investments -592.96146.0634.470000000
Others 25.750.390.020054.67-54.16-0.55-11.3518.99
Cash Flow From Financing Activity 460.63-188.0768.6816.09-56.28-284.93-3.69-45.63-30.29-41.17
Net Proceeds from Shares 79.69000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -24.93-36.65-22-53.58-57.82-31.52-7.85-1.36-1.15-0.85
Dividend Paid -91.74-83.88-60.86-0.94000000
Others 497.61-67.53151.5470.621.54-253.414.16-44.27-29.15-40.32
Net Cash Flow 6.63-71.87-43.440.15-0.551-1.980.180.24-0.90
PARTICULARSMar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Ratios
ROE (%)25.7520.6318.072.86-14.49-1.41-33.720.993.04-196.05
ROCE (%)19.1515.0212.94.53-6.290.67-19.880.692.14-106.58
Asset Turnover Ratio0.370.330.310.110.060.030.030.040.060.05
PAT to CFO Conversion(x)0.48-0.13-0.39-0.37N/AN/AN/A4.651.2N/A
Working Capital Days
Receivable Days1291322208331,5751,540225062137
Inventory Days1091391635559751,4821,40938893127
Payable Days58251013301,5211,682202235628

Opto Circuits (India) Ltd Stock News

Opto Circuits (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Opto Circuits (I) on 23-May-2022 18:01 is ₹1.78.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-May-2022 18:01 the market cap of Opto Circuits (I) stood at ₹53.51.
The latest P/E ratio of Opto Circuits (I) as of 23-May-2022 18:01 is 0.00.
The latest P/B ratio of Opto Circuits (I) as of 23-May-2022 18:01 is -0.44.
The 52-week high of Opto Circuits (I) is ₹1.94 and the 52-week low is ₹1.78.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Opto Circuits (I) is ₹0.25 ( Cr.) .

About Opto Circuits (India) Ltd

Opto Circuits India (OCI), incorporated in the year 1992 is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries. The manufacturing is backed by a complete range of inspection and reliability testing equipments such as Bond Pull, Shear Testers, Stereo Microscopes, IR Viewers Spectrometers and many more.

OCI specialize in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies. Its products are US FDA listed and CE marked. Some of the well-known brands marketed by the company are Criticare Systems, Mediaid, Unetixs Vascular, Eurocor and Cardiac Science.

The company has customers in USA, Europe, Middle East, Far East, South Africa etc. To service these customers it has offices through its subsidiaries in USA, Germany, Singapore and Dubai. It has subsidiaries namely Mediaid Inc (USA), Eurocor Gmbh (Germany), Criticare Systems Inc (USA), Advanced Micronic Devices (India), Devon Innovations (India), ORMED Medical Technology (India) and Altron Industries (India).

It clients includes names like Manipal Groups of hospitals, Escorts Heart Hospital, Wockhardt Heart Hospitals, Apollo Group of Hospitals, Lilavati hospital, Breach Candy Hospital are among others.

In January 2009, the company’s California-based Mediaid Inc., the subsidiary company and the international marketing arm of the company had received Brazilian FDA agency - Agencia Nacional de Vigilancia Sanitaria (ANVISA) - approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.

During December, 2010 Opto Circuits (India) has successfully acquired 76% of outstanding common stock of Cardiac Science Corporation US. The company plans to exercise its top-up option under the terms of the merger agreement. The merger is expected to occur in the next few days. Following the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits (India).

Products

Health Care products- Under this segment it manufactures Pulse Oximeters, Pulse Oximeter Sensors, Fluid warmers, Digital Thermometer,Cholesterol Monitors And Stent.

Opto Electronics products- The Company manufactures Infrared Emitters, Infra Red Detectors, Photo Sensor, Detector and Emitter Assemblies.

Recognition

The company has ISO 9001-2000 and ISO 13485-2003 quality system certification.

OCI has received 2 Star Trading House Status in accordance with the provisions of Exim Policy of Federal Government of India.

Opto Circuits (India) has been featured in Forbes Asia’s 200 ‘Best Under a Billion’ List, 2011 by Forbes magazine. This is the third time the company has made it to this list, the last two times being 2008 and 2009.

Milestones

2010
- Opto Circuits acquisition of Unetixs Vascular creates strong synergies for Criticare Systems.
- Opto Circuits Successfully Completes Acquisition of Cardiac Science.
- Opto Circuits forays into manufacturing of cardiac stents - acquires Kolkata based N.S. Remedies.

2011
- Opto Circuits presents Bangalore Metro Rail Corporation Ltd. it's first public access defibrillator.
- Opto Circuits launches campaign to promote heart safe environments on World Heart Day.
- Opto Circuits ranked amongst Forbes' Asia's 200 Best Under a Billion companies for third year.

2012
- Opto Circuits launches new Powerheart G5 AED.
- Opto Circuits Supplies AEDs to 2012 UEFA European Football Championship.
- Opto Circuits launches its first Sirolimus Drug Eluting Stent."

 

Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...